4Takashi T,Hagowara A,Shimotsuma M,et al.Prophylaxis and treatment of peritoneal carcinomatosis:intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles[J].World J Sur,1995,19:265.
5Kailara N,Zitsuka Y,Kimura A,et al.Relationship between area of serosal invasion and prognosis with gastric carcinoma[J].Cabeer,1987,60(2):136.
6Elias D,E Otmany A,Bonnay M,et al.Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosils[J].Oncology,2002,63:346-352.
7Witkamp A J,de Beer E,Van Goethem R,et al.Rationale and techniques of intra-operative hyperthermic intrapcritoneal chemotherapy[J].Cancer Treat Rev,2001,27:365-374.
8Sugarbalker P H.Cwnliffe W J,Belliveau J,et al.Rationale for interrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer[J].Semin Oncol,1989,16(1):83.
9Stephen R L,Novak J M,Jensen EM,et al.Effect of osmotic pressure on uptake of chenotherapeutic agents by carcinoma cells[J].Cancer Res,1990,50:4704-4708.
4Baldwin LA, Huang B, Miller RW, et al. Ten-year relative sur- vival for epithelial ovarian cancer [ J ]. Obstet Gynecol, 2012, 120:6124518.
5Woo HH, Laszlo CF, Greco S, et al. Regulation of colony stim- ulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152[J]. Mol Cancer, 2012, 11:58.
6Campbell S. Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening[ J]. Ultrasound Obstet Gyne- col, 2012, 40:245-254.
7Twu C, Han ES. Clinical utility of targeted treatments in the management of epithelial ovarian cancer [ J ]. Biologics, 2012, 6:233-244.
8Wintzell M, Hjerpe E, Avall-Lundqvist E, et al. Protein mark- ers of cancer-associated fibroblasts and tumor-initiating cells re- veal subpopulations in freshly isolated ovarian cancer ascites [J]. BMC Cancer, 2012, 12:359.
